Bupivacaine

證據等級: L5

預測適應症: 4 個

Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans

One-Sentence Summary

Bupivacaine is a long-acting amide-type local anesthetic, widely used for regional nerve blocks, epidural anesthesia, and surgical pain management via sodium channel blockade. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans — a late-stage Lyme disease–associated chronic skin atrophy — however, this prediction is currently supported by 0 clinical trials and 0 publications, representing the weakest possible evidence tier.

Quick Overview

Item	Content
Original Indication	Local/regional anesthesia and perioperative pain management
Predicted New Indication	Acrodermatitis Chronica Atrophicans
TxGNN Prediction Score	99.23%
Evidence Level	L5
Taiwan Market Status	✗ Not Registered
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on well-established pharmacological knowledge, bupivacaine is a voltage-gated sodium channel (Nav) blocker belonging to the amide class of local anesthetics. By preventing Na⁺ influx, it interrupts action potential propagation in sensory and motor nerves, producing reversible local anesthesia. Secondary to this primary mechanism, in vitro studies have documented weak anti-inflammatory activity — including inhibition of NF-κB signalling and suppression of pro-inflammatory cytokines such as IL-6 — though these effects occur at concentrations far exceeding clinically relevant levels.

Acrodermatitis chronica atrophicans (ACA) is a dermatological manifestation of late disseminated Borrelia burgdorferi infection (Lyme disease), characterised by progressive skin atrophy and chronic low-grade inflammation. The hypothesised mechanistic link relies on bupivacaine's incidental anti-inflammatory properties reducing local cutaneous inflammation — not on any antibacterial or spirochaetal activity. This indirect chain (Na⁺ channel blockade → anti-inflammatory → Borrelia-driven skin atrophy) is pharmacologically tenuous at best.

The repurposing rationale documented in the Evidence Pack itself flags a high likelihood of knowledge graph artefact: TxGNN's high prediction score may stem from co-occurrence bias between "skin inflammation" nodes in the training graph rather than a genuine drug–disease pharmacological signal. With zero supporting clinical or preclinical evidence in the direct indication space, this prediction should be treated as a hypothesis-generating signal only, not a viable repurposing candidate at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Bupivacaine is not currently registered with the Taiwan Food and Drug Administration (TFDA). No marketing authorizations or approved products were found in the regulatory database query conducted on 2026-03-29.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert data and formal contraindication/warning records were not retrievable from the data pipeline at the time of this report (Data Gap: DG001). Before any preclinical or clinical investigation proceeds, a full safety profile review from the originator label (e.g., Marcaine®/AstraZeneca) and TFDA database must be completed. Key known class-level concerns include cardiac toxicity (QRS widening, ventricular arrhythmia) and direct myotoxicity — the latter is particularly relevant given the dermatomyositis-spectrum predictions in ranks 2 and 4.

Conclusion and Next Steps

Decision: Hold

Rationale: All four predicted indications carry L5 evidence (model prediction only, no supporting clinical trials or literature), and the mechanistic link between bupivacaine's sodium channel blockade and Borrelia-driven chronic skin atrophy is indirect and unvalidated. Additionally, the simultaneous appearance of two dermatomyositis-spectrum predictions at high scores raises a credible concern that TxGNN's output reflects graph topology clustering artefacts rather than true pharmacological signals.

To proceed, the following is needed:

Complete safety data retrieval: Download and parse the TFDA package insert PDF for bupivacaine to populate contraindications, boxed warnings, and drug interaction profiles (DG001 — Blocking severity)
MOA confirmation: Retrieve full DrugBank MOA entry to formally document sodium channel subtype selectivity and anti-inflammatory evidence thresholds (DG002 — High severity)
Knowledge graph audit: Evaluate whether TxGNN's high scores for all four indications reflect true pharmacological signal or systematic over-scoring of "skin/connective tissue inflammation" node clusters
Preclinical literature sweep: Conduct a broader PubMed search using MeSH terms for "bupivacaine + anti-inflammatory" and "local anesthetic + dermatitis" to identify any foundational mechanistic evidence before considering in vitro work
Route compatibility assessment: Even if mechanistic plausibility were established, an appropriate delivery route for a chronic skin condition (topical formulation? intradermal depot?) would need to be defined, as systemic bupivacaine carries unacceptable cardiac risk for non-surgical indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.